SNORA81: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORA81

NCBI ID: G677847

SNORA81

Other Name(s): small nucleolar RNA, H/ACA box 81 | Small nucleolar RNA, H/ACA box 81 | HBI-61

SNORA81: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. H/ACA box 81 (SNORA81) is a specific snRNA molecule that has been identified as a potential drug target and biomarker. In this article, we will explore the structure and function of SNORA81, its potential implications as a drug target, and its potential as a biomarker for various diseases.

Structure and Function

SNORA81 is a 24.8 kilobase (kb) long RNA molecule that contains 1,032 unique amino acid residues. It is characterized by the presence of a specific H/ACA box, which is a conserved region that is present in many snRNAs. The H/ACA box is a transcribed region that is responsible for the initiation of the translation of the RNA molecule.

SNORA81 has been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have shown that SNORA81 can interact with various protein molecules, including histone(H3K9me3), H2A.Z, and RNA-binding protein( RBP). These interactions can alter the stability and localization of SNORA81, which may influence its function in gene regulation.

In addition to its role in gene regulation, SNORA81 has also been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that SNORA81 is overexpressed in various cancer types, and that inhibition of SNORA81 has been shown to enhance the efficacy of chemotherapy in various models of cancer.

Potential Drug Target

SNORA81 has been identified as a potential drug target due to its unique structure and function. The H/ACA box on SNORA81 has been shown to be a potential drug target, as many drugs that are currently in use have been shown to interact with this region . For example, inhibition of SNORA81 using small molecules or RNA-based therapies has been shown to be effective in treating various diseases, including cancer.

In addition to its potential as a drug target, SNORA81 has also been shown to be a potential biomarker for various diseases. The expression of SNORA81 has been shown to be affected by a variety of factors, including cancer, and that changes in SNORA81 expression levels can be used as a diagnostic or predictive factor for various diseases.

Biomarker Potential

SNORA81 has been shown to be involved in the regulation of gene expression in various diseases, including cancer. As a potential drug target, SNORA81 has the potential to be used in the treatment of various diseases, including cancer. The expression of SNORA81 has been shown to be affected by a variety of factors, including cancer, and that changes in SNORA81 expression levels can be used as a diagnostic or predictive factor for various diseases.

Conclusion

SNORA81 is a unique small nucleolar RNA molecule that has been shown to play a role in the regulation of gene expression in various organisms, including humans. Its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand the role of SNORA81 in disease progression and its potential as a drug and biomarker.

Protein Name: Small Nucleolar RNA, H/ACA Box 81

The "SNORA81 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA81 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets